CC
KZR

Centiva Capital’s Kezar Life Sciences KZR Stock Holding History

Centiva Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,780
Closed -$88.7K – 2394
2024
Q2 		$88.7K Buy
+14,780
New +$112K ﹤0.01% 1873

Other funds holding KZR

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Centiva Capital's KZR Position: Q3 2024 in Review

Centiva Capital sold out of Kezar Life Sciences (KZR) in Q3 2024, closing a stake of 14,780 shares — an estimated $88.7K sold.

Centiva Capital first reported a position in KZR in Q2 2024 and held it in 1 quarter. The position peaked at $88.7K in Q2 2024. 59 funds tracked by Wall St. Rank hold KZR as of Q3 2024.

  • Centiva Capital reported no remaining Kezar Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 14,780 Kezar Life Sciences shares in Q3 2024, an estimated $88.7K.
  • Centiva Capital first reported a position in Kezar Life Sciences in Q2 2024 and held it in 1 quarter.
  • Centiva Capital's Kezar Life Sciences position peaked at $88.7K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.